What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...

GLP-1 and nutrition: managing risks for at-risk patients. Dr Almandoz shares key insights on malnutrition risks in post-bariatric and older patients, plus how to tailor care for better outcomes.

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

GLP-1s and nutrition: quality over restriction! Dr Almandoz shares how shifting from restrictive diets to evidence-based, ...

In this article, we will look at the 10 Best Performing Healthcare Stocks So Far in 2025.

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

Several local companies are developing technologies that they hope could replace a painful poke with something that feels more like having Velcro against your skin for a few minutes.

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging ...

Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.